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OsteoporosisThe large variety of biological functions governed by prostaglandin (PG) E2 is mediated by signaling through
four distinct E-type prostanoid (EP) receptors. The availability of mouse strains with genetic ablation of each
EP receptor subtype and the development of selective EP agonists and antagonists have tremendously
advanced our understanding of PGE2 as a physiologically and clinically relevant mediator. Moreover, studies
using disease models revealed numerous conditions in which distinct EP receptors might be exploited
therapeutically. In this context, the EP4 receptor is currently emerging as most versatile and promising
among PGE2 receptors. Anti-inﬂammatory, anti-thrombotic and vasoprotective effects have been proposed
for the EP4 receptor, along with its recently described unfavorable tumor-promoting and pro-angiogenic roles.
A possible explanation for the diverse biological functions of EP4 might be the multiple signaling pathways
switched on upon EP4 activation. The present review attempts to summarize the EP4 receptor-triggered signaling
modules and the possible therapeutic applications of EP4-selective agonists and antagonists.
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Table 2
EP2/EP4 receptor agonists.
Name Dose,
concentration,
afﬁnity
Model, species References
11-Deoxy-PGE1 100 nM–50 μM Bone resorption,
mouse
Sakuma et al., 2000
γ-Lactam PGE
analog 2a
1.7 μg/kg Bronchodilation,
guinea pig
Xiao et al., 2008
γ-Lactam PGE
analog 4
30–300 μg/kg Bone fracture healing,
rat
Kambe et al., 2012
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Prostaglandins (PGs) and thromboxane A2 (TXA2) are synthesized
from arachidonic acid by cyclooxygenase (COX) and speciﬁc
prostanoid synthases. Released in response to various physiological
and pathological stimuli they play essential roles in maintaining
body homeostasis. Prostaglandin E2 (PGE2) is involved in several bio-
logical processes such as pain, fever, regulation of vascular tone, renal
function, mucosal integrity, inﬂammation, angiogenesis and tumor
growth. PGE2 often causes complex and divergent effects which can be
attributed to its activation of four so-called E-type prostanoid receptors
(EP1 to EP4). Studies conducted with EP receptor knock-out mice and
the recent availability of highly selective pharmacological agonists and
antagonists have allowed us to identify distinct — although sometimes
overlapping— roles for EP receptor subtypes in PGE2-regulated process-
es. In this review,we summarize the physiological roles of EP4, itsmolec-
ular structure and intracellular signaling pathways, and how EP4
receptors might be targeted pharmacologically for the beneﬁt of
human disease, including vascular and renal diseases, inﬂammation, os-
teoporosis and cancer. Tables 1–3 provide an overview of currently de-
scribed selective and non-selective agonists, and antagonists for EP4,
respectively, and their afﬁnity, dosing and biological effects.
2. Prostaglandin E2 and its four receptors
Prostanoids are derived from arachidonic acid, a 20 carbon poly-
unsaturated fatty acid, which is usually found in phosphoglycerides
of mammalian cell membranes (Fig. 1). Arachidonic acid is released
by phospholipase A2 from the cell membrane and is converted
to PGG2 and then reduced to PGH2 by COX-1 or COX-2 (Smith &
Dewitt, 1996; Park & Christman, 2006). In general COX-1 is constitu-
tively active whose expression appears to be regulated developmen-
tally, while COX-2 is usually absent from cells but its expression canTable 1
EP4 receptor-selective agonists.
Name Dose, concentration, afﬁnity Model, spec
AGN205203 Ki = 81 nM
3 mg/kg
HEK-EP4, hu
Colitis, mou
APS-999 Na 50 μg/animal Ovarian foll
Cay10598 (19a) Ki = 1.2 nM HEK-EP4, hu
CP-044,519-02 10 mg/kg/day Acute and c
EP4RAG 1–3 mg/kg Myocardial
10–50–100 nM THP-1 mono
L-902688 10 nM–10 μM Bronchi, hum
10 nM–10 μM Pulmonary
Lubiprostone 50–500 nM Short circuit
and submuc
ONO-4819CD 36 ng/kg Ulcerative c
300 μg/kg Cardiac isch
1–30 μg/kg 3× a day Inhibition o
ONO AE1-329 25–100 μg/kg Colitis, mou
10 nM–10 μM Bronchi, hum
30 nM Eosinophil i
100 nM Aortic rings
10 nM–10 μM Pulmonary
1 μM Ductus arter
300 μg/kg Cardiac isch
30–100 μg/kg Hepatic isch
30–300 μg/kg Cerebral isc
30 nM Human pulm
3–30 nM Human plat
800 nM/kg/day Bone forma
ONO AE1-734 0.1 mg/kg/day Colitis, mou
PGE1-OH 10–1000 nM Human derm
TCS 2510 1 μM Renal epithe
10 μM GLP-1 relea
γ-Lactam PGE analog 3 30–300 μg/kg Bone fracturbe induced in response to different stimuli. However, COX-2 is also
constitutively expressed in some tissues, such as the endothelium,
kidney, gastrointestinal mucosa and brain (O'Banion, 1999; Grosser
et al., 2006; Zidar et al., 2009). The endoperoxide intermediate
PGH2 is converted to the different prostanoids (PGE2, PGI2, TXA2,
PGD2, PGF2α) by speciﬁc synthases. In general, the expression pattern
of the prostanoid synthases is speciﬁc for different cells and
determines which prostanoid they will be producing in abundance.
PGE2 is generated at large amounts in ﬁbroblasts, monocytes, and
epithelial and endothelial cells by three enzyme isoforms, i.e. inducible
microsomal PGE synthase-1, and constitutively expressed microsomal
PGE synthase-2 and cytosolic PGE synthase (Fig. 1) (Kudo & Murakami,
2005).
The various biological effects of PGE2 are mediated by four EP
receptors, which show differential patterns of tissue distribution.
EP1 mRNA is ubiquitously expressed in murine tissues, while EP3
receptor mRNA levels are high in adipose tissues, pancreas, kidney
and vena cava. EP4 mRNA is mainly expressed in the gastrointestinal
tract, uterus, hematopietic tissues and skin, whereas EP2 receptories References
man
se
Jiang et al., 2007
icle growth, rat El-Neﬁawy et al., 2005
man Billot et al., 2003
hronic kidney failure, rat Vukicevic et al., 2006
dysfunction, rat Hishikari et al., 2009
cyte migration Hishikari et al., 2009
an Benyahia et al., 2012
vein, human Foudi et al., (2008)
current in tracheal epithelium
osal gland secretion, sheep
Cuthbert, 2011
olitis, human Nakase et al., 2010
emia, mouse Maruyama et al., 2002
f bone loss, de novo bone formation, rat Yoshida et al., 2002
se Nitta et al., 2002
an Benyahia et al., 2012
nhibition, human Konya et al., 2011 and
Luschnig-Schratl et al., 2011
, mouse Hristovska et al., 2007
vein, human Foudi et al., 2008
iosus smooth muscle cells, rat Maruyama et al., 2002 and
Yokoyama et al., 2006
emia, mouse Maruyama et al., 2002
emia, mouse Kuzumoto et al., 2005
hemia, mouse Liang et al., 2011
onary endothelial barrier Konya et al., 2013
elet aggregation Philipose et al., 2010
tion, mouse Yoshida et al., 2002
se Kabashima et al., 2002
al microvascular endothelial angiogenesis Zhang and Daaka, 2011
lial cell proliferation, mouse Liu et al., 2012
se, mouse GLUTag cells Coskun et al., 2013
e healing, rat Kambe et al., 2012
487V. Konya et al. / Pharmacology & Therapeutics 138 (2013) 485–502mRNA was found to be least abundant among EP receptors, with the
highest expression occurring in the airways, ovary, bone marrow
and olfactory epithelium (Regard et al., 2008). The EP receptors are
coupled to different G proteins and accordingly activate diverse
signaling pathways (Fig. 1) (Alfranca et al., 2006). EP1 signals predom-
inantly via Gq, thereby elevating intracellular Ca2+ levels through the
action of phospholipase Cβ followed by activation of protein kinase
(PK) C. EP2 and EP4 are described as Gs coupled receptors, which
activate adenylate cyclase and induce intracellular cyclic adenylyl
monophosphate (cAMP) production, while EP3 is coupled to Gi and
inhibits cAMP production (Alfranca et al., 2006). The human EP1 recep-
tor is comprised of 402 amino acids, the EP2 from358, the EP3 from390
while the EP4 receptor is composed of 488 amino acids, additionally
there are two alternative splice variants of the EP1 and eight variants
of the EP3 (Regan, 2003). A similar tendency can be observed inmurine
EP1, EP2, EP3 and EP4 receptors, which consist of 405, 362, 366 and 513
amino acids, respectively (Negishi et al., 1993; Sugimoto & Narumiya,
2007).
3. E-type prostanoid receptor 4 structure, signaling and ligands
3.1. Structure
When ﬁrst cloned in 1993 as a PGE2 receptor that stimulated
cAMP formation, the EP4 receptor was designated as “EP2” (Honda
et al., 1993). After another cAMP-stimulating PGE2 receptor had been
discovered which was sensitive to butaprost (Regan et al., 1994), the
butaprost-insensitive receptor whichmediated vasorelaxation in piglet
saphenous vein was renamed “EP4” (Coleman et al., 1994; Nishigaki
et al., 1995; Breyer et al., 1996).
The EP4 gene contains three exons of which the ﬁrst is non-
coding. The initiation site was found to lack a TATA box, but it is
GC-rich, and contains two CCAAT boxes and SP1-, AP2- and NF-
κB-binding motifs (Foord et al., 1996). Across EP receptors in humans
and mice, most amino acid conservation can be found in the trans-
membrane helices which form the binding pocket for the natural
ligand PGE2 (Fig. 2) (Stillman et al., 1998). Amino acid homology
among the EP receptor subtypes is small, between single EP receptors
not more than 30%. Even EP2 and EP4 receptors, which are both
coupled to Gαs proteins and activate adenylate cyclase, share only
38% homology in humans and 31% in mice (Regan, 2003; SugimotoTable 3
EP4 receptor-selective antagonists.
Name Dose, concentration, afﬁnity Model, species
AH-23848 25–125 ng/g Angiogenesis, mou
BGC20-1531 pK(B) 7.6–7.8; 1–10 mg/kg i.v. Cerebral and meni
CJ-023,423 56–97 mg/kg Bone destruction a
CJ-042,794 10–30 mg/kg LPS-induced TNF-α
Diphenyloxazole 8 Ki = 0.3 nM [3H]PGE2 binding s
ER-819762 10–100 mg/kg/day Arthritis, mouse, ra
GW627368x 1 μM Eosinophils, huma
1 μM Pulmonary vein, h
10 μM Platelet aggregatio
L-161982 300 nM Macrophages, hum
MF191 1 mg/kg Bladder overactivit
MF498 1–30 mg/kg Analgesia in rheum
Joint pain in osteo
ONO AE2-227 300 ppm in diet Reduced formation
ONO AE3-208 10 mg/kg/day Colitis, mouse
100–300 nM Eosinophil, human
10 nM Aortic rings, mous
300 nM Pulmonary endoth
100–300 nM Platelet aggregatio& Narumiya, 2007). Regarding the interaction of PGE2 with the EP4
receptor, a single threonine residue, T168, in the second extracellular
loop was identiﬁed as being essential (Fig. 2) (Stillman et al., 1998).
Furthermore, the very recent 3D modeling of the human EP4 receptor
and in silico docking experiments for PGE2 revealed the most likely
binding sites of PGE2 on the 3D structure of EP4. These pertinent
amino acid residues are S103, T168, Y186, F191, L195, S285,
and D311 (Fig. 2) (Margan et al., 2012). Radioligand binding studies sug-
gested that the afﬁnity of PGE2 for EP4 receptors is higher (EC50: 2.8 nM)
than that for EP2 (EC50: 19 nM) (Fujino et al., 2002).
3.2. Signaling pathways
The EP4 receptor was initially described as a Gαs protein-coupled
receptor leading to stimulation of adenylate cyclase and elevation of
intracellular cAMP levels (Coleman et al., 1994). EP4 stimulation,
among other functions, induces vascular relaxation mediated by cAMP,
PKA and endothelial nitric oxide synthase (eNOS) (Hristovska et al.,
2007), and angiogenesis via cAMP and PKA Cμ (Zhang & Daaka, 2011)
(Fig. 2). The transcription factor cAMP-responsive element-binding pro-
tein (CREB) can be phosphorylated by PKA or different MAP kinases
(Johannessen et al., 2004; Johannessen & Moens, 2007). CREB regulates
the expression of FcγRIIA, an important receptor of neutrophils and
monocytes in combating bacterial infections. Endogenous or exoge-
nously added PGE2 activates CREB through PKA in the differentiation
of the myeloid PLB cell line, an effect that depends on EP4 receptors
(Hazan-Eitan et al., 2006). In monocytes, EP4 receptor-mediated CREB
activation and binding to the promotor of the chemokine receptor
CCR7 enhances the expression of the receptor and augments themigra-
tion of the cells (Cote et al., 2009). Alternatively, cAMP can act through
inducible cAMP early repressor (ICER), a truncated CREB analog that
binds to cAMP response-element but blocks transcription, as it lacks
the trans-activation domain. EP4 receptor activation has been found
to reduce retinoic acid secretion by ICER-mediated blockade of the
expression of retinoic acid dehydrogenase (Stock et al., 2011).
An additional EP4 receptor signalingmolecule independent of PKA is
Epac, i.e. the exchange protein activated by cAMP. Epac-1 and Epac-2
are guanine nucleotide-exchange factors that link cAMP and members
of the Ras superfamily such as Rho, Rac and Ras. As such, Epac signaling
is generally involved in cell proliferation, differentiation, migration, and
inﬂammatory responses (Bos, 2003). Epac and PKA can signalReferences
se Zhang and Daaka, 2011
ngeal arteries, carotid blood ﬂow, human Maubach et al., 2009
nd inﬂammation in arthritis, rat Okumura et al., 2008
production in whole blood, human Hatazawa et al., 2007
and Murase et al., 2008
tudies, IgE synthesis in B cells, mouse Hattori et al., 2005
t Chen et al., 2010
n Luschnig-Schratl et al., 2011
uman Foudi et al., 2008
n, human Philipose et al., 2010
an Takayama et al., 2002
y, rat Chuang et al., 2012
atoid arthritis, rat
arthritis, guinea pig
Clark et al., 2008
of preneoplastic lesions, mouse Mutoh et al., 2002
Kabashima et al., 2002
Konya et al., 2011
and Luschnig-Schratl et al., 2011
e Hristovska et al., 2007
elial barrier, human Konya et al., 2013
n, human Philipose et al., 2010
Fig. 1. PGE2 biosynthesis and receptors. Arachidonic acid is liberated from membrane phospholipids by phospholipase A2 enzyme activity. Arachidonic acid is converted to the
endoperoxide PGG2 and further reduced to PGH2 by the action of cyclooxygenase 1 and 2 enzymes. PGE2 is formed from PGH2 by PGE synthases and binds to and activates four
EP receptor subtypes, designated EP1 to EP4 receptors. These receptors are coupled to different G proteins leading to subsequent activation of speciﬁc signal transduction pathways.
Besides PGE2, other prostanoids are also formed from PGH2, i.e. PGI2, TXA2, PGD2 and PGF2α. Additionally, PGE2 can also be converted to PGA2.
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Fig. 2. The structure of the EP4 receptor and its activation of signaling modules. The 488 amino acid sequence of the human EP4 receptor is displayed with color code indicating the
single residues conserved in all EPs, the binding sites for the native ligand PGE2, regions responsible for desensitization and for interaction with EPRAP. Binding of an agonist induces
Gαs-dependent activation of adenylate cyclase (AC), formation of cAMP and either activation of Epac (exchange factor activated by cAMP), activation of the PKA-independent
AMP-activated protein kinase (AMPK) or activation of PKA and eNOS, or alternatively the transcription factor CREB (cAMP-responsive element-binding protein). Additionally,
cAMP can act through inducible cAMP early repressor (ICER). EP4 receptor activation has been found to reduce retinoic acid secretion by ICER-mediated blockade of the expression
of retinoic acid dehydrogenase These signals ﬁnally mediate vascular relaxation, angiogenesis and protection against cerebral ischemic injury. EP4 receptor becomes rapidly
desensitized upon binding of G protein-coupled receptor kinases (GRK) to serine residues on the C-terminus. These residues are phosphorylated and attract β-arrestin initiating
receptor internalization, and c-Src which leads to transactivation of EGFR and further activation of PI3K/ERK/Akt kinases. Alternatively, Pertussis toxin-sensitive Gαi can be activated
which also may induce the activation of PI3K/ERK pathway. These latter signaling pathways enable migration and metastasis of colorectal carcinoma and inhibit the activation of
eosinophils in allergic inﬂammation. The extended C-terminus of EP4 receptor allows interaction with EPRAP which in turn stabilizes the p105 subunit that prevents the activation
of NF-κB and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase kinase 1/2 (MEK/ERK1/2), and inhibits transcription of pro-inﬂammatory cytokines in
activated macrophages.
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490 V. Konya et al. / Pharmacology & Therapeutics 138 (2013) 485–502synergistically, as shown for the closure of ductus arteriosus (Yokoyama
et al., 2008). Finally, EP4 receptors in podocytes signal to induce COX-2
through an indirectly cAMP-dependent, PKA-independent signaling
pathway: AMP-activated protein kinase (AMPK) (Faour et al., 2008).
Therefore, PGE2–EP4 signaling can activate multiple cAMP-dependent
pathways, including PKA, Epac and AMPK, which might act in concert
or in alternating manner to mediate Gαs-dependent effects of the EP4
receptor.
Moreover, its C-terminus exhibits potential phosphorylation sites
for PKA and G protein-coupled receptor kinases (GRK), and might
provide additional interaction sites for other signaling molecules
such as arrestins or EP4 receptor-associated protein (EPRAP) (Desai
& Ashby, 2001; Regan, 2003; Takayama et al., 2006). Most probably,
these signaling pathways are activated in parallel and explain the
much weaker cAMP response to PGE2 in EP4 receptor-transfected
cells as compared to EP2-transfected cells (Fujino et al., 2002).
Additionally, EP4 receptor-overexpressing CHO cells showed rapid
desensitization and internalization of EP4 after PGE2 stimulation,
which was not observed with EP2 receptors (Nishigaki et al., 1996).
Furthermore, differential N-glycosylation also inﬂuences the mainte-
nance of receptor surface expression (Ludwig et al., 2000). EP4 receptor
has two putative N-glycosylation sites, while EP2 has four. The amino
acid residues in the EP4 receptor responsible for desensitization were
identiﬁed on the long C-terminal tail as six serine residues in positions
370, 371, 374, 377, 379, 382. These residues are potential targets of
phosphorylation by PKA and GRK (Fig. 2) (Bastepe & Ashby, 1999;
Desai et al., 2000). The phosphorylation of EP4 receptor recruits
β-arrestin-1 which in turn activates c-Src to initiate the transactivation
of the epidermal growth factor receptor (EGFR) and subsequent
downstream signaling through phosphatidyl insositol 3-kinase (PI3K)
and Akt (Buchanan et al., 2006). The activation of this signaling cascade
has been proposed to regulate themigration andmetastasis of colorectal
carcinomas (Fig. 2) (Buchanan et al., 2006).
EP4 receptor can additionally couple to the Pertussis toxin-sensitive
inhibitory G-protein (Gαi) that also leads to activation of PI3K/ERK
signaling in EP4 receptors overexpressed in HEK293 cells (Fig. 2)
(Fujino et al., 2003; Fujino & Regan, 2006). EP4 receptor ligation
induced in vivo neurovascularization in mice, and in vitro endothelial
migration and tube formation via ERK signaling (Rao et al., 2007). EP4
receptor-mediated protection in a cerebral ischemia mouse model
was found to depend on the Akt/eNOS pathway (Liang et al., 2011).
In addition, a recent report from our lab demonstrated that inhibition
of eosinophil function by an EP4 receptor-selective agonist (ONO
AE1-329) depends on PI3K/PKC but not on cAMP/PKA (Luschnig-
Schratl et al., 2011).
Further increasing the complexity of EP4 receptor signaling, a bind-
ing site for EPRAP has been identiﬁed on the long cytoplasmic tail of EP4
in human macrophages (Takayama et al., 2006). EPRAP was shown to
stabilize the p105 subunit of NF-κB that in turn prevents the activation
of NF-κB and mitogen-activated protein kinase kinase/extracellular
signal-regulated kinase kinase 1/2 (MEK/ERK1/2), and further inhibits
the transcription of pro-inﬂammatory cytokines (Fig. 2) (Minami
et al., 2008). Utilizing this G protein-independent mechanism, EP4
receptors play an anti-inﬂammatory role in human and murine macro-
phages and might inhibit the proliferation of a mouse immature B lym-
phocyte cell line (Takayama et al., 2006; Minami et al., 2008; Prijatelj
et al., 2012).
3.3. Ligand-based signaling pathways
In view of the distinct signaling pathways originating from EP4, the
question arises whether different EP4 receptor ligandsmay differentially
trigger these signaling modules. The ﬁrst study to systematically
compare the activation of Gαs, Gαi and β-arrestin signaling pathways re-
vealed characteristic differences between various ligands and native
PGE2 (Leduc et al., 2009). In bioluminescence resonance energy transfer(BRET) assays investigating HEK293 cells overexpressing EP4 receptor,
PGE2 activated Gαs with 10-fold higher potency over Gαi, while other
ligands, such as the EP4 receptor agonists L-902688 and PGE1-OH,
were biased towards Gαi and β-arrestin over Gαs. All these responses
were shown to be mediated by EP4 receptors using the EP4-speciﬁc
antagonist GW627368X (Leduc et al., 2009). EP4 receptor-selective
agonists and EP2/EP4 receptor agonists are listed in Tables 1 and 2,
respectively. EP4 receptor-selective antagonists are shown in Table 3.
4. Immune modulation by E-type prostanoid receptor 4
COX inhibitors, also referred to as non-steroidal anti-inﬂammatory
drugs (NSAIDs), are widely used for symptomatic treatment of inﬂam-
matory diseases, particularly due to their potent analgesic effect.
However, their clinical use is considerably limited as they give rise to
gastrointestinal, renal and cardiovascular complications, among others.
Selective COX-2 inhibitors that had been developed to minimize
adverse effects by sparing the homeostatic functions of COX-1 did not
meet expectations due to increased cardiovascular risk (Grosser et al.,
2010). This Janus head nature of prostaglandins is consistent with the
numerous pro- and anti-inﬂammatory effects that PGE2 can exert,
which might be up to local concentrations of PGE2 and expression
patterns of its receptors. The anti-inﬂammatory actions of PGE2 have
been mainly ascribed to the EP4 receptor (Tang et al., 2012), although
the EP2 receptor may play similar, redundant roles in many cellular
and in vivo models. Nevertheless, the EP4 receptor might also act
to promote inﬂammation, particularly in Th17-dependent diseases
(Sheibanie et al., 2007; Sakata et al., 2010), and is widely considered
as an important pro-tumorigenic molecule (Chell et al., 2006).
The EP4 receptor is expressed on most immune cell types, and
functional responses mediated by EP4 receptors have been reported in
B- and T-lymphocytes, natural killer cells, dendritic cells, eosinophils,
monocytes and macrophages (Norel, 2007; Kalinski, 2012). PGE2 and
EP4 receptors are indispensable for monocyte-derived dendritic cells
and Langerhans cells to attain a migratory phenotype (Luft et al.,
2002; Kabashima et al., 2003), which is a prerequisite for them to
evade into lymph nodes and subsequently present antigens there.
EP2/EP4-mediated expression of matrix metalloprotease-9 in dendritic
cells appears to be crucial for their migration (Yen et al., 2011).
Concomitantly, cytokine release from these cells is inhibited while
survival is enhanced by the EP4 receptor (Luft et al., 2002; Jing et al.,
2003; Baratelli et al., 2005).
Recently, PGE2 was recognized to positivelymodulate the differenti-
ation and activity of Th17 cells. EP4 receptor stimulation accentuates
LPS-induced IL-23 secretion from immature dendritic cells and super-
natants from these cells enhance IL-17 production in activated T cells
(Sheibanie et al., 2007). Naïve T cells upregulate IL-23 and IL-1 receptors
in response to EP2/EP4 signaling and PGE2 synergizes with these
cytokines in promoting the typical Th2 phenotype, whereby EP4 recep-
tor stimulation particularly leads to IL-10 downregulation (Boniface
et al., 2009; Napolitani et al., 2009). In vivo, the EP4 antagonist
ONO-AE3-208 ameliorated experimental autoimmune encephalomy-
elitis or contact hypersensitivity, and reduced IL-17 production in
regional lymph nodes (Yao et al., 2009). In contrast, human plasmacytoid
dendritic cells produce less interferon-α following EP2/EP4 stimulation
by PGE2 and lose their Th1 co-stimulatory capacity (Fabricius et al., 2010).
Dendritic cells that mature in the presence of PGE2 preferably
drive Th2 polarization, and produce Th2-attracting chemokines,
which might argue for a crucial role of EP4 receptors in allergic sensi-
tization (Kubo et al., 2004; McIlroy et al., 2006). This notion is further
supported by the observation that PGE2 promotes the differentiation
of B-cells and the class-switch to IgE through EP2 and EP4 receptors
(Fedyk & Phipps, 1996). In contrast, PGE2 suppresses antigen-
speciﬁc responses, such as proliferation and cytokine secretion of
human Th1- and Th2 cells through EP2/EP4 signals (Okano et al.,
2006), suggesting that PGE2 might limit allergic responses upon
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suppression following UV irradiation of the skin, an effect that was due
to accumulation of self-tolerant, DEC205-expressing, dendritic cells and
CD4+/Foxp3+ regulatory T cells in peripheral lymph nodes, but was
not observed in mice treated with an EP4 antagonist (Soontrapa et al.,
2011).
4.1. Macrophages, atherosclerosis and sepsis
PGE2 has a dual effect on macrophages; on the one hand stimulat-
ing their motility (Tajima et al., 2008), on the other hand suppressing
the release of inﬂammatory chemokines. Macrophages stimulated
with LPS and pro-inﬂammatory cytokines, such as TNF-α, IFN-γ and
IL1-β showed markedly reduced secretion of IL-8, MCP-1, MIP-1α
and β and IP-10 upon PGE2 pretreatment (Takayama et al., 2002).
Macrophages express the EP4 receptor, and all these anti-inﬂammatory
effects of PGE2 were suppressed by the selective EP4 antagonist
L-161982. However, this anti-inﬂammatory response to PGE2 was not
mediated by the cAMP/PKA/CREB pathway. The signaling pathway
involved was identiﬁed to include a novel cytoplasmic signaling partner
of the EP4 receptor, designated as EP4 receptor-associated protein
(EPRAP) (Takayama et al., 2006). In human atherosclerotic plaques,
EPRAP co-localized with the EP4 receptor, and siRNA targeting of
EPRAP limited the PGE2-induced anti-inﬂammatory effects in macro-
phages, while the PGE2-induced cAMP increase was not signiﬁcantly
affected. EPRAP shows the highest degree of homology with the murine
feminization 1 homolog a (Fem1a), which is a homolog of the
Caenorhabditis elegans FEM-1 protein. The FEM-1 protein is involved in
the regulation of transcription factors in the sex-determination cascade
of C. elegans. Furthermore, EPRAP contains 8 sequential ankyrin repeats,
which suggests its potential involvement in protein–protein interaction.
Such ankyrin repeats can be found e.g. in nuclear factor (NF)-κB and IκB
(Malek et al., 1998). The actual interaction of EP4 receptor and EPRAP
with NF-κB was shown subsequently by the same group (Minami
et al., 2008). In macrophages, the LPS-induced NF-κB activation was
observed to be blocked by PGE2. In detail, LPS treatment of macrophages
induces the phosphorylation of NF-κB1 p105, which leads to its degrada-
tion, and in turn allows the activation of NF-κB and the subsequent tran-
scription of pro-inﬂammatory genes. At this point, the EP4 receptor-
associated EPRAP stabilizes the p105 subunit by preventing its
phosphorylation and degradation, thereby inhibiting NF-κB and
mitogen-activated protein kinase kinase 1/2 (MEK) in macrophages
(Minami et al., 2008). EP4 receptor activation was also found to
attenuate cytokine release from human alveolar macrophages (Ratcliffe
et al., 2007). In a very similar manner, PGE2 acting via EP4 receptors
attenuated the activation of microglia and prevented lipid peroxidation
and proinﬂammatory gene expression in a murine model of LPS-
induced brain inﬂammation (Shi et al., 2010).
Macrophages play an important role in lipid homeostasis in the
vasculature, pertinent to atherosclerosis. The role of EP4 receptors was
addressed by allogenic hematopoietic cell transplantation from mice
deﬁcient in EP4 receptors to animals lacking the low density lipoprotein
receptor. EP4 deﬁciency in hematopoietic cells partially protected
against early atherosclerotic lesions (Babaev et al., 2008), but enhanced
the inﬂammation in advanced atherosclerotic plaques and facilitated
the formation of angiotensin II-induced abdominal aortic aneurysms
(Tang et al., 2011a, 2011b). In sharp contrast, systemic treatment
of mice with the EP4 antagonist, ONO-AE3-208, or a heterozygous
EP4+/− genotype decreased vascular inﬂammation and protected
from angiotensin II-induced abdominal aortic aneurysm formation on
an ApoE-deﬁcient background (Cao et al., 2012; Yokoyama et al.,
2012). These observations might suggest that EP4 receptors in hemato-
poietic and somatic cells play opposing roles in vascular homeostasis.
Sepsis is characterized by uncontrolled activation of inﬂammatory
cascades, often followed by a shift toward an immunosuppressive
state (Hotchkiss & Karl, 2003). In a recent study, arachidonic acidmetabolites like TXB2, 5-HETE and PGE2 were quantiﬁed using a sen-
sitive mass spectrometry approach in whole blood samples of pa-
tients with severe sepsis (Bruegel et al., 2012). Most strikingly, PGE2
and PGE synthase levels were reduced in blood samples of septic pa-
tients, both at baseline and also following ex vivo stimulation with
LPS. The positive regulatory role of PGE2 in sepsis was further sup-
ported by an increase of PGE2 release in patients with a favorable
clinical course of the disease (Bruegel et al., 2012). However,
the EP receptor mediating the protective role of PGE2 in sepsis
has not yet been identiﬁed, but it is likely that EP4 receptor-mediated
suppression of monocyte cytokine release plays a major role (Iwasaki
et al., 2003).
A previous study, using a mouse sepsis model induced by
cecal ligation and puncture, demonstrated that administration of bone
marrow stromal cells suppressed macrophage activation by increasing
the secretion of IL-10 and leading to amelioration of multi-organ
inﬂammation. PGE2 was revealed to mediate this response via EP4
and EP2 receptors on macrophages (Nemeth et al., 2009). As such, the
EP4 receptor and EPRAP might provide novel therapeutic targets in
chronic inﬂammatory diseases with excess of macrophage activation,
such as atherosclerosis and sepsis.
4.2. Eosinophils and allergic inﬂammation
Inﬁltration of eosinophils, a major effector cell type involved
in allergic inﬂammation and asthma, was found to be markedly
enhanced in COX-1 and COX-2 knockout mice (Gavett et al., 1999).
This suggested a possible inhibitory effect of prostaglandins on
eosinophils. In fact, stimulation of EP4 receptor by ONO AE1-329
and PGE2 effectively inhibited eosinophil function including chemo-
tactic responses, CD11b adhesion molecule expression and formation
of reactive oxygen species (Luschnig-Schratl et al., 2011). On the
subcellular level, EP4 receptor activation resulted in blockade of cyto-
skeletal reorganization and inhibition of intracellular Ca2+ release. All
these effects were reversed by antagonizing the EP4 receptor using
GW627368x and ONO AE3-208. The EP4-mediated inhibition of
eosinophil function depended on PI3K and PKC but not the cAMP/
PKA pathway (Luschnig-Schratl et al., 2011). Moreover, activation of
EP4 receptors attenuated the interaction of eosinophils with human
pulmonary microvascular endothelial cells, with respect to adhesion
under physiological ﬂow conditions and transendothelial migration
of eosinophils (Konya et al., 2011). EP4 agonist treatment inhibited
cell surface clustering of β2 integrins and L-selectin shedding of
eosinophils, which were all abolished using ONO AE3-208 (Konya
et al., 2011). Interestingly, in a model of allergic airway inﬂammation,
mice lacking EP4 had only slightly increased inﬂammatory cell
inﬁltration in the lung compared to wild type mice, while EP3
knock-out mice developed much more pronounced allergic inﬂam-
mation (Kunikata et al., 2005). This latter ﬁnding suggests that
murine studies cannot be easily extrapolated to human pathobiology.
5. Airways
In the pulmonary environment, PGE2 attenuates inﬂammatory
responses and reduces tissue injury of the airways (Vancheri et al.,
2004). Additionally, COX-1 and -2 deﬁcient mice show increased
allergic responses in the airways (Gavett et al., 1999; Nakata et al.,
2005). Consequently, selective COX-1 and -2 inhibitors enhanced
allergic inﬂammation and airway hyperresponsiveness (Peebles
et al., 2002). PGE2 was also shown to play a bronchoprotective role
in patients with asthma (Pavord et al., 1993; Melillo et al., 1994;
Aggarwal et al., 2010). Similarly, intratracheal administration of
PGE2 diminished the ovalbumin-induced early and late phase airway
responses in rats (Martin et al., 2002). Isolated tracheal and bronchial
preparations frommice, rats, guinea pigs, monkeys and humans were
all relaxed by PGE2, and this effect was mediated by the EP4 receptor
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species (Buckley et al., 2011; Benyahia et al., 2012). These important
observations — EP4 receptor-mediated inhibitory effect on eosinophil
effector functions and direct bronchodilator action — might contrib-
ute to the development of next generation bronchodilators as an
alternative to the widely used β2 adrenoceptor agonists, which fail
to treat the underlying tissue inﬂammation.
Consistent with its bronchoprotective action, PGE2 inhibited
bronchial smooth muscle cell proliferation and migration through
EP4 (Sastre et al., 2011; Aso et al., 2013). Moreover, EP4 receptor
activation caused apoptosis in human adult lung ﬁbroblasts by reducing
the expression of survivin, an inhibitor of apoptosis and attenuating Akt
activity (Huang et al., 2009), and partiallymediated the inhibitory effect
of PGE2 on the migration of human fetal ﬁbroblasts in a cAMP/PKA/
PI3K-dependent manner (Y.J. Li et al., 2011). Therefore, EP4 agonists
might be a useful therapeutic intervention for airway inﬂammatory
diseases such as asthma and chronic bronchitis due to their
bronchoprotective, antiﬁbrotic and anti-inﬂammatory effects. In
contrast, blockade of EP4 receptors reversed the senescence of
lung ﬁbroblasts from COPD patients, suggesting a potential usefulness
of EP4 receptor antagonists in COPD (Dagouassat et al., 2013).
6. Gastrointestinal tract
It is long known that NSAIDs contribute to worsening of gastro-
intestinal mucosal damage and inﬂammation in humans, and are a
major risk factor for ulcer disease and gastrointestinal hemorrhage
(Kaufmann & Taubin, 1987; Bjarnason et al., 1993; Felder et al.,
2000; Laine et al., 2008). Experimental gastric damage as induced
by the COX inhibitor indomethacin or by a mixture of ethanol plus
HCl in mice and rats are ameliorated by PGE2 and an EP1 agonist
(Suzuki et al., 2001; Takeuchi et al., 2001), while duodenal and intes-
tinal lesions are prevented by EP3 and EP4 agonists (Kunikata et al.,
2001; Kunikata et al., 2002). Part of the EP4 receptor-mediated intesti-
nal mucosal protection might be due to stimulation of duodenal bicar-
bonate and mucus secretion (Takeuchi et al., 1997; Araki et al., 2000;
Aihara et al., 2007), its anti-apoptotic effect on epithelial cells (Hoshino
et al., 2003), vasodilation (Hattori et al., 2008) and vascular endothelial
growth factor (VEGF) release to promote angiogenesis and mucosal
healing (Hatazawa et al., 2007).
Consistent with the anti-inﬂammatory action of prostaglandins in
the gut, COX-1 and -2 deﬁcient mice show augmented colitis induced
experimentally by oral administration of dextran sodium sulfate
(DSS) (Morteau et al., 2000). The involvement of EP receptors was
addressed by inducing colitis with 3% DSS in mice deﬁcient for DP,
EP1, EP2, EP3, FP, IP or TP receptor (Kabashima et al., 2002). Only
EP4 receptor deﬁcient mice developed severe colitis, similar to mice
treated with the EP4-selective antagonist ONO AE3-208. Switching
off the EP4 receptor abolished the mucosal barrier function and led
to edema formation, damage of the epithelial layer and inﬁltration
of immune cells, e.g. neutrophils and CD4+ T cells in the colon. Two
different EP4-selective agonists, ONO AE1-734 and AGN205203,
reversed the pathology of DSS colitis in wild-type mice, an effect that
was strongly suppressed by an EP4 antagonist. On the cellular level,
EP4 receptor stimulation protected against colon epithelial apoptosis,
prevented goblet cell depletion, and promoted the regeneration of the
epithelial layer. A substantial observation was the upregulation of EP4
mRNA following DSS-induced colitis in mice and rats (Kabashima
et al., 2002; Nitta et al., 2002; Jiang et al., 2007).
These results were at variance with a study that addressed the role
of EP4 receptors in a different, more severe, model of colitis induced
by trinitrobenzene sulfonic acid. EP4 receptor stimulation by PGE1-
OH ormisoprostol, a non-selective EP receptor agonist, aggravated coli-
tis and reduced survival rate, which was attributed to EP4 receptor-
mediated IL-23 secretion from dendritic cells leading to accumulation
of IL-17-producing cells in the colon (Sheibanie et al., 2007). Theseseemingly contradicting ﬁndings of EP4 receptors being beneﬁcial in
one colitis model, but deleterious in the other more severe model,
might be due to the inhibitory role of EP4 receptors in ﬁbroblast migra-
tion, thereby hampering wound healing and tissue repair (Rieder et al.,
2010).
A clinical pilot study recently addressed the protective effect of the
EP4 receptor agonist ONO-4819CD, a prodrug, in a small group of
patients (four patients in the active treatment group, three in the
placebo group) suffering from mild-to-moderate ulcerative colitis
(Nakase et al., 2010). A tendency towards improvement of clinical symp-
toms as well as histological scores was noted in EP4 agonist-treated
patients.
Disruption of the intestinal mucosal barrier is characteristic
in several gastrointestinal diseases including ischemia–reperfusion,
inﬂammatory bowel disease and NSAID-induced gastropathy (DeMeo
et al., 2002). PGE2 was shown to induce gastrointestinal anion secretion
as a mechanism of mucosal barrier protection (Bunce & Spraggs, 1990).
PGE2 stimulated chloride secretion in ischemia-injured porcine ileal
mucosa, which was followed by signiﬁcant increase in transepithelial
electrical resistance referring to recovery of epithelial barrier function
(Moeser et al., 2004). The chloride channel ClC-2 was identiﬁed as
the principal path for this response and showed co-expression with
occludin in epithelial tight junctions (Moeser et al., 2004). Lubiprostone,
a PGE1 derivative, was also shown to enhance gastrointestinal mucosal
barrier function and was characterized as a selective activator of ClC-2,
acting very similar to PGE2 (Moeser et al., 2007). Lubiprostone is
currently approved for the treatment of chronic constipation in the
U.S.A., Switzerland, United Kingdom and Japan. In rat and human gut
preparations lubiprostone was found to interact with EP1 and EP4
receptors (Bassil et al., 2008) and to increase the expression of
ClC-2 and cystic ﬁbrosis transmembrane conductance regulator
(CFTR). Moreover, lubiprostone induced contraction of villi and proxi-
mal colonic plicae and increased mucus exocytosis in goblet cells (Jakab
et al., 2012). Similar to its gastrointestinal effects, lubiprostone was
shown to stimulate tracheal submucosal gland secretion in pigs, sheep
and humans without producing bronchoconstriction (Joo et al., 2009).
An EP4-selective antagonist (L-161982) prevented the lubiprostone-
induced chloride transport and submucosal gland secretion in sheep
airways, and an EP4 agonist (L-902688) mimicked the effects of
lubiprostone (Cuthbert, 2011). In a human airway epithelial cell line,
EP4 receptor stimulation increased chloride efﬂux through CFTR (Joy
& Cowley, 2008). Consequently, lubiprostone and other EP4 agonists
could ﬁnd therapeutic application in diseases with reduced airway
ﬂuid secretion.
7. Vasculature
The EP4 receptor has been ﬁrst identiﬁed owing to its role in the
PGE2-induced relaxation of the piglet saphenous vein (Coleman
et al., 1994). In this ﬁrst report, the EP1, EP2 and EP3 receptors
were ruled out as being responsible for the vasodilator effect of
PGE2 and, thus, the existence of a fourth EP receptor was proposed.
Today, it is generally accepted that activation of EP1 and EP3 receptor
subtypes induces vasoconstriction, whereas the EP2 and EP4 recep-
tors expressed on smooth muscle cells mediate vasodilation (Norel,
2007). The EP4 receptor was further established as an important
regulator of vascular tone in isolated perfused rat kidneys where the
PGE2-induced relaxation of renal afferent arterioles was EP4 receptor-
dependent (Tang et al., 2000). Coupling to Gαs and the subsequent for-
mation of cAMP determined the observed vasorelaxation. A different
signaling pathway was proposed to mediate the vasorelaxing effect of
EP4 receptors in aortic rings of mice where increased eNOS activity
and intracellular cGMP accumulation were found (Hristovska et al.,
2007). The PGE2-induced relaxation was mimicked by an EP4 agonist
(ONO AE1-329), and reversed by an EP4 receptor antagonist (ONO
AE3-208). Consistent with these ﬁndings, relaxation was attenuated
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in EP2−/− mice. Moreover, the in vivo hypotensive response to PGE2
was attenuated in eNOS-deﬁcient mice (Hristovska et al., 2007).
EP4-selective agonists also induced relaxation of the human pulmonary
vein, an effect that was prevented by blockade of EP4 receptors. In
contrast, the pulmonary artery was not relaxed after EP4 receptor
activation. Accordingly, smoothmuscle cells of pulmonary vein express
more EP4mRNA than cells isolated from pulmonary artery (Foudi et al.,
2008).
7.1. Ductus arteriosus
EP4 deﬁciency in mice is perinatally lethal. Ninety ﬁve percent of
animals were found to die due to patent ductus arteriosus, the fetal
vessel that bridges the pulmonary and systemic circulation until
birth (Segi et al., 1998). The remaining 5% survived and lived on for
a year with partially closed DA. The patency of ductus arteriosus
during the fetal period was presumed to be maintained principally
by the dilator effect of the EP4 receptor, while its closure was thought
to be induced by immediate withdrawal of the dilator prostaglandin
PGE2 as well as active contraction exerted by increased oxygen
tension (Smith, 1998). Later studies in rats revealed that EP4 receptor-
mediated signals promote ductus arteriosus closure by hyaluronic acid
accumulation to form an intimal cushion at birth, by stimulating the
migration and hyaluronic acid production of smooth muscle cells
(Yokoyama et al., 2006). The paradox of patent ductus arteriosus
is that vasodilator EP4 receptors are needed for maintaining patency
of the ductus in fetal life; however, EP4 receptor expression decreases
before birth but still induces intimal cushion formation which leads
to direct closure of the ductus. Thus, ductus arteriosus closure is
not merely due to vasoconstriction as previously believed (Ivey &
Srivastava, 2006). In rodents, ductus arteriosus closure occurs
within hours after birth, while in humans, due to its larger diameter,
closure of the ductus requires highly developed intimal cushion forma-
tionwhich takes several days to be completed (Gentile et al., 1981; Tada
& Kishimoto, 1990). Therefore, studies in larger mammals are required
to clarify whether EP4 agonists are directly applicable to neonatal med-
icine to improve the outcomes of low birth-weight infants who suffer
from patent ductus arteriosus.
7.2. Ischemia
The potential beneﬁcial roles of EP receptors in cardiovascular func-
tion have been reviewed recently (J.-i. Suzuki et al., 2011; Tang et al.,
2012). Endogenous PGE2, by stimulating EP4 receptors was found to
be cardioprotective in a murine cardiac ischemia/reperfusion model
(Xiao et al., 2004). EP4−/− mice showed increased cardiac infarct size
as compared to wild-type mice. Among EP receptors, the EP4 receptor
was shown to be highly expressed in the mouse heart and exclusively
mediated the protective effects of PGE2. The EP4 receptor agonists,
ONO AE1-329 and ONO-4819-CD (300 μg/kg subcutaneously), a pro-
drug for in vivo application that is converted to an active metabolite
in the circulation (Maruyama et al., 2002), were cardioprotective via
activating cAMP (Xiao et al., 2004). However, the mechanisms of
how elevation of intracellular cAMP levels exerts cardioprotection in
ischemia has not yet been elucidated yet, but might reﬂect EP4
receptor-mediated vasodilator or platelet inhibitory responses as
described below (Philipose et al., 2010). An additional important
aspect of the EP4 receptor-mediated cardioprotective function
was reported in rats, where EP4RAG, an EP4-selective agonist,
prevented myocardial dysfunction after infarction (Hishikari et al.,
2009). These experiments revealed that EP4 receptor activation
leads to suppression of inﬂammatory cytokines, including TNF-α,
IL-1β, IL-6, and MCP-1, thereby limiting the inﬁltration of macro-
phages at sites of ischemia/reperfusion. Furthermore, EP4RAG
attenuated the activity of matrix metalloprotease-2 and -9 in thetissue, and inhibited MCP-1-induced migration of monocytes in
vitro, which might have added to the cardioprotective action of
the EP4 receptor (Hishikari et al., 2009). The anti-inﬂammatory
potential of the EP4 receptor in the heart was further demonstrated
by the same group in models of murine heart transplantation and
rat autoimmune myocarditis (Ogawa et al., 2009; Ngoc et al., 2011).
PGE2 has also been described to protect against liver injury caused by
ischemia/reperfusion, chemotoxicity and bacterial infection (Stachura
et al., 1981; Miyazaki et al., 1983; Takano et al., 1998). These protective
effects were hypothetically explained by increased liver perfusion, anti-
platelet effect, inhibition of cytokine release and direct cytoprotective
function of PGE2 (Masaki et al., 1992). Out of the four EP receptors only
EP4 receptors were found to be upregulated on hepatocytes in an ische-
micmousemodel (Kuzumoto et al., 2005). Activation of EP4 receptors by
the EP4-selective agonist ONO AE1-329 provided strongest protection
against hepatic injury as compared to other selective EP receptor
agonists. In detail, the EP4 agonist reduced the serum levels of hepatic
injury markers and inhibited the release of proinﬂammatory cytokines
such as TNF-α and IFN-γ, and the chemokines MCP-1 and IP-10, and
also decreased the expression of E-selectin and ICAM-1 adhesion
molecules in the ischemic liver (Kuzumoto et al., 2005). Importantly,
neutrophil inﬁltration into the liver was also found to be attenuated
after EP4 receptor stimulation. The high therapeutic potential of EP4
receptors in the liver was unequivocally indicated by the observation
that 80% of lethally injured mice treated with an EP4 agonist were alive
two days after reperfusion, while only 14% of vehicle-treated mice
survived (Kuzumoto et al., 2005).
Prostaglandins play controversial roles in neurological disorders
as activation of COX, particularly COX-2, has been shown to worsen
cerebral injury in several animal models (Hewett et al., 2006).
At the same time, patients taking COX-2 inhibitors are at increased
cerebrovascular and cardiovascular risk, because COX-2 inhibition
selectively removes the inhibitory effect of vascular PGI2 synthesis
on platelet activity without attenuating COX-1-derived thromboxane
synthesis in platelets (Funk & FitzGerald, 2007). Supporting the
beneﬁcial effects of COX metabolites, the EP4 receptor was reported
to play a protective role in a mouse model of cerebral ischemia
(Liang et al., 2011). Treatment of mice after ischemia with ONO
AE1-329 reduced infarct size and prevented long-term locomotor
deﬁcits. EP4 receptors were found to abound on neurons and became
markedly upregulated in endothelial cells after ischemia/reperfusion,
suggesting that the dual EP4 receptor signaling of neurons and
endothelial cells imparts cerebroprotection. Conditional deletion of
neuronal or endothelial EP4 receptors aggravated the cerebral deﬁcits
and decreased cerebrovascular reperfusion in the same study.
Increased levels of activated eNOS in cerebral microvessels following
EP4 agonist treatment were proposed to underlie the cerebral pro-
tective effect of the EP4 agonist. The inhibitory effects of EP4 receptor
activation on macrophages and the implications of EP4 receptors in
vascular inﬂammation and atherosclerosis are discussed above.
7.3. Platelet aggregation
An important prerequisite of cardiovascular homeostasis is tight
regulation of platelet aggregation. We recently observed that stimula-
tion of EP4 receptors on human platelets inhibits platelet aggregation
and in vitro thrombus formation of human whole blood (Philipose
et al., 2009, 2010). Similar observations were reported in parallel
by three other groups (Iyu et al., 2010; Kuriyama et al., 2010; Smith
et al., 2010). The EP4 agonist ONO AE1-329 attenuated the pro-
aggregatory effect of ADP with an IC50 value of 30 nmol/L, that of
platelet activating factor with an IC50 value of ~10 nmol/L and those
of collagen and the thromboxane mimetic U46619 with an IC50
value of 3 nmol/L. Two different EP4 antagonists completely reversed
the inhibitory effect of ONO AE1-329 on platelet aggregation, and
rendered PGE2 to being a potent pro-aggregatory mediator. The
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characterized by reduced intracellular Ca2+ mobilization and phos-
phorylation of vasodilator-stimulated phosphoprotein (VASP), inhibi-
tion of glycoprotein IIb/IIIa activation, and downregulation of
P-selectin (Iyu et al., 2010; Kuriyama et al., 2010; Philipose et al.,
2010). Surprisingly, ONO AE1-329 was at least 30-times less potent
in inhibiting the aggregation of rat, guinea pig and mouse platelets
than that of human platelets (Kuriyama et al., 2010; Philipose et al.,
2010). Moreover, the anti-aggregatory response to PGE2 in mice
was observed to be mediated by the IP receptor rather than the EP4
receptor as revealed by IP- and EP4-deﬁcient mice, respectively
(Fabre et al., 2001; Kuriyama et al., 2010). These ﬁndings shed light
on the previously described dual effect of PGE2 on platelet aggrega-
tion, namely that at lower concentration PGE2 potentiated, while at
higher concentration inhibited, platelet aggregation (Salzman et al.,
1972; Shio et al., 1972; Weiss et al., 1976; Thierauch & Prior, 1991;
Vezza et al., 1993). From these studies it may be inferred that
the pro-aggregatory effect of PGE2 in human platelets is mediated
by EP3 receptors, while EP4 receptors are responsible for its
anti-aggregatory properties (Matthews & Jones, 1993; Mao et al.,
1996; Ma et al., 2001; Gross et al., 2007; Heptinstall et al., 2008).7.4. Endothelial function
PGE2 alongwith PGI2 has been shown to increase humanpulmonary
artery endothelial barrier function. Particularly, PGE2 was shown to re-
duce dextran permeability of resting and thrombin-stimulated human
pulmonary artery endothelial cells and to enhance endothelial electrical
resistance via cAMP/PKA/Rap1/Rac signaling (Birukova et al., 2007). In a
recent study we have identiﬁed the EP4 receptor as being responsible
for the enhanced endothelial barrier function in response to PGE2
(Konya et al., 2013). Using human pulmonarymicrovascular endothelial
cells as a model system, we observed that only an EP4 receptor agonist
(ONOAE1-329), but not EP1, EP2 and EP3 agonistsmimicked the barrier
enhancing effect of PGE2 (Fig. 3). Similar responses were recorded in
human coronary artery endothelial cells. The barrier enhancement
was totally abolished by an EP4 antagonist (ONO AE3-208) and by
preventing actin polymerization. On the cellular level PGE2 and the
EP4 agonist induced cortical actin polymerization and enhanced endo-
thelial junctional expression of VE-cadherin (Fig. 3). Interestingly, the
classical cAMP/PKA signalingmodule, eNOS or Rac1, PI3K or p38 kinases
were not involved in this system. Additionally, EP4 receptor activation
facilitated wound healing of pulmonary microvascular endothelial
monolayers. Endothelial E-selectin upregulation, neutrophil adhesionFig. 3. The EP4 receptor promotes endothelial barrier function. EP4 receptor activation indu
junctions, which results in markedly increased electrical resistance of the cell monolayer
migration as induced by TNF-α treatment is prevented by EP4 receptor activation. EP4 re
of the generally used EP4 receptor signaling modules (cAMP, eNOS, Rac1, PI3K, p38, ERK1/2) a
MAP kinase pathway mediates the EP4 receptor-stimulated release of IL-8 in endothelial cells.and transmigration, induced by TNF-α pretreatment of endothelial
cells, were also inhibited by endothelial EP4 receptor stimulation. The
reduction of E-selectin expression depended on PI3K/PKC kinases. How-
ever, the exactmechanismof EP4 receptor-mediated endothelial barrier
function awaits further investigation. Taken together, these observa-
tions indicate that EP4 agonists offer a potential novel approach to dis-
eases with increased vascular permeability and neutrophil extravasation
(Birukova et al., 2007; Konya et al., 2013).
By contrast, another recent report suggested that human pulmonary
microvascular endothelial cells show enhanced release of the chemokine
IL-8 upon stimulation with PGE2 or ONO AE1-329 for 24 h (Aso et al.,
2012). This pro-inﬂammatory action of EP4 receptors was mediated by
cAMP/PKA and p38 MAP kinase but without involving ERK1/2 (Fig. 3).
Whether the EP4 receptor-induced IL-8 release from endothelial cells
actually results in neutrophil recruitment to the tissue has not yet
been addressed, but similar EP4 receptor-mediated expression of pro-
inﬂammatory cytokines was observed in airway and colon epithelial
cell lines (Dey et al., 2009; T. Li et al., 2011). On a similar line, EP4 recep-
tor activation in murine cerebrovascular endothelial cells upregulated
intercellular adhesion molecule-1 (ICAM-1) expression (Park et al.,
2013).7.5. Angiogenesis
Beside its vasoprotective effects, PGE2 can induce angiogenesis of
endothelial cells (Salcedo et al., 2003). Further studies demonstrated
that PGE2 and EP4 receptor-selective agonists (PGE1-OH and ONO-
AE1-329) induced migration and tubulogenesis of pulmonary
microvascular endothelial cells derived from control mice, while
they had no effect on EP4 deﬁcient endothelial cells (Rao et al., 2007).
The EP4 agonist did not induce cell proliferation but stimulated
endothelial cell migration, an effect that depended on ERK, but was
independent of the classical cAMP pathway. Additionally, the same
EP4 agonists promoted angiogenesis in vivo (Rao et al., 2007; Zhang &
Daaka, 2011). Likewise, inﬂammatory lymphangiogenesis promoting
the formation of granulation tissue in matrigel plugs was abrogated in
EP3- and EP4-deﬁcient mice (Hosono et al., 2011).
In human umbilical vein endothelial cells (HUVEC) PGE2 induced
angiogenesis by activating the NO/cGMP signaling pathway via PKA/
PI3K/Akt-dependent elevation of eNOS activity (Namkoong et al.,
2005). Activation of EP4 receptors by PGE2 promoted in vitro tube
formation in human neonatal dermal microvascular endothelial cells,
ex vivo vessel outgrowth ofmurine aortic rings, and in vivo angiogenesis
in sponge implants in mice (Zhang & Daaka, 2011). The selectiveces rapid cortical actin polymerization and VE-cadherin expression in the endothelial
. Furthermore, E-selectin upregulation, and leukocyte adhesion and transendothelial
ceptor-mediated E-selectin down-regulation is PI3K/PKC-dependent; however, none
re involved in the barrier-enhancing effect of EP4 receptor. In contrast, the cAMP/PKA/p38
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antagonists, and siRNA knock-down of the receptor. EP4 receptor activa-
tion in endothelial cells caused intracellular cAMP formation. In agree-
ment with this observation, elevation of intracellular cAMP by
forskolin has previously been reported to stimulate angiogenesis via
PKA-mediated VEGF expression and Epac-dependent PI3K/Akt/eNOS
signaling (Namkoong et al., 2009). Further signaling pathways in the
pro-angiogenic effect of EP4 stimulation were elucidated to include
EP4 receptor coupling to Gαs, activation of PKA catalytic subunit γ,
and activation of Rap1A, HSPB6 and eNOS, i.e. known phosphorylation
targets of PKA that have been shown to mediate tube formation
(Zhang & Daaka, 2011). These ﬁndings clearly demonstrate that EP4
receptors mediate PGE2-induced angiogenesis in mouse and human
endothelial cells. Interestingly, this occurs in mice in an ERK-associated
but PKA-independent manner, whereas it depends on cAMP/PKA/eNOS/
cGMP pathways in human endothelial cells.
Collectively, a large body of evidence suggests that EP4 agonists
might be promising novel approaches to control vascular disease
due to the broad biological functions of the EP4 receptor in vascula-
ture. These include anti-ischemic, vasodilator, and platelet inhibitory
actions, stimulation of endothelial barrier function and angiogenesis,
complemented by anti-inﬂammatory properties.
8. Kidney
PGE2 plays diverse and important roles in the regulation of renal
function (Hao & Breyer, 2008). Accordingly, the kidney is a major
target of adverse effects of COX inhibitors particularly in the elderly,
which include salt retention, hypertension, and blunted renal
function (Harirforoosh & Jamali, 2009). Among the EP receptors,
EP4 receptor (and to some extent EP2) is key to renal homeostasis
by regulating cell proliferation, vascular tone and renin secretion.
Cultured juxtaglomerular cells show pronounced renin secretion
in response to PGE2 and EP4 agonists (Friis et al., 2005). This
response appears to bemediated by cAMP-dependent hyperpolarization
and inhibition of Ca2+ currents that paradoxically inhibit renin-
containing granule exocytosis. In vivo, low salt diet stimulates kidney
renin mRNA levels and plasma renin concentrations in wild-type mice
but not in EP4 knock-outmice or inmice treatedwith the EP4 antagonist
ONO-AE3-208 (Poschke et al., 2012). Similar results were obtained in
mice treated with furosemide (Nusing et al., 2005; Facemire et al.,
2011). Vascular tone in the kidney also depends on EP4 receptors: the
PGE2-induced vasodilatation at low concentrations is abolished, while
EP1-mediated vasoconstriction at higher concentrations of PGE2 is
augmented, in EP4-deﬁcient mice (Purdy & Arendshorst, 2000;
Schweda et al., 2004).
PGE2 and EP receptors including EP4 play important roles in
kidney development, as suggested by a reduced glomerular size in
EP4-deﬁcient mice (Frolich et al., 2012). In vitro, PGE2 acting via
EP4 receptors augmented the survival of glomerular epithelial cells
deprived of serum (Aoudjit et al., 2006), and an EP4 receptor agonist
stimulated proliferation and decreased apoptosis of renal epithelial
cells (Yamamoto et al., 2010). PGE2 and EP4 receptors have been
suggested to be involved in autosomal dominant polycystic kidney dis-
ease, as they induce proliferation and chloride secretion in polycystin-1
deﬁcient epithelial cells, while inhibiting proliferation in polycystin-1
expressing cells (Liu et al., 2012).
Several other pathologies of the kidney are counterbalanced by the
PGE2/EP4 axis, suggesting that EP4 agonists might be a useful thera-
peutic option in renal disease. In a mouse model of renal diabetes
insipidus, EP4 receptor stimulation with ONO AE1-329 compensated
the loss of vasopressin V2 receptors probably by activating aquaporin-
2 in tubule epithelial cells (Li et al., 2009; Olesen et al., 2011). The
same EP4 receptor agonist protected against anti-glomerular basement
membrane antibody-associated nephritis in mice (Nagamatsu et al.,
2006). In a murine model of ureteral obstruction, the developmentof renal ﬁbrosis, the accumulation of macrophages, and the formation
of proinﬂammatory and proﬁbrotic cytokines were signiﬁcantly
augmented in the kidneys of EP4 knock-out mice and suppressed by
an EP4 agonist, ONO-4819 (Nakagawa et al., 2012). In a mercury
chloride-induced rat model of acute kidney failure, a systemically
administered EP4 agonist (CP-044,519-02) reduced serum creatinine
levels and increased the survival rate of the animals (Vukicevic et al.,
2006). Similarly, treatmentwith the EP4 agonist delayed the progression
of chronic renal failure as induced by 5/6 nephrectomy (Vukicevic et al.,
2006).
In contrast, podocyte-speciﬁc overexpression of EP4 receptors sig-
niﬁcantly aggravated, while deletion of EP4 receptors in podocytes
ameliorated, the decline of renal function in 5/6 nephrectomized
mice (Stitt-Cavanagh et al., 2010). Interestingly, there is a positive
feedback in PGE2 secretion, as COX-2 expression is induced in
podocytes following EP4 stimulation through a PKA-independent
mechanism (Faour et al., 2008), and COX-2 and EP4 receptors are
found upregulated in compromised or regenerating tubule epithelial
cells (Yamamoto et al., 2010; Nakagawa et al., 2012). EP4 receptor ex-
pression in glomeruli is increased following salt deprivation as are
PGE2-evoked cAMP and renin responses in juxtaglomerular cells
(Jensen et al., 1999). The EP4 receptor-induced stimulation of sodium
absorption prompted by an activated renin/angiotensin II/aldosterone
system is counterbalanced by the natriuretic action of EP1 receptors
and diuretic action of EP3 receptors in the collecting duct (Fleming
et al., 1998; Guan et al., 1998; Tamma et al., 2003).
9. Bone and cartilage
Osteoporosis is a bone degenerative disease of the elderly, induced
by the imbalance of bone resorption by osteoclasts and bone forma-
tion by osteoblasts. Such loss of bone density increases the incidence
of bone fractures. Among prostaglandins, PGE2 shows the most
prominent activity in bone, being involved both in bone formation
and resorption (Norrdin et al., 1990). The dual role of prostaglandins
in bone dynamics is also reﬂected by epidemiological data showing
that chronic use of COX-2 inhibitors is associated with reduced bone
mineral density in males, while the opposite effect is observed in
postmenopausal women not taking hormone replacement therapy
(Richards et al., 2006). In clinical practice, COX inhibitors are being
used to control ectopic bone formation, but their use in the treatment
of fracture pain has raised concern with respect to a potential delay of
fracture healing (Vuolteenaho et al., 2008).
Bone resorption is carried out by osteoclasts, which originate from
bone marrow-derived mononuclear cells. EP1 and EP4 receptors were
found to be highly expressed in a mouse osteoblastic cell line,
and stimulation of EP4 receptors by 11-deoxy-PGE1, a purported EP4 re-
ceptor agonist, promoted osteoblast differentiation (Suda et al., 1996).
PGE2 was found to induce in vitro osteoclast formation from bonemar-
row cells in the presence of primary murine osteoblasts, which was
mimicked by 11-deoxy-PGE1. Additionally, osteoclast formation in re-
sponse to PGE2, but also to TNFα, IL-1β or LPS,was ablated in cells isolated
from EP4 deﬁcient mice (Sakuma et al., 2000). In agreement with these
data, an EP4 antagonist was found to attenuate LPS-induced osteoclast
formation and bone destruction in rat periodontal tissue (Oka et al.,
2012).
In contrast, osteoclast differentiation from human peripheral blood
monocytes is blocked by EP4 receptor activation (Take et al., 2005). At
the same time, EP4 receptors also seem to play a role in the bone ana-
bolic effect of PGE2. COX-2 deﬁcient mice presented with impaired
healing of fractures, which was reversed by EP4 agonist treatment
(Xie et al., 2009). EP4-deﬁcient mice showed impaired bone formation
in vivo in response to PGE2, while other EP receptor-deﬁcient mice
exhibited unchanged callus formation (Yoshida et al., 2002). The effect
of PGE2 was mimicked by the EP4 agonist ONO AE1-329. Consistently,
the EP4 agonist also induced the formation of mineralized nodules in
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mice. Moreover, the same study reported that the EP4 agonist ONO
4819CD promoted de novo bone formation in experimental rat
models of osteoporosis, induced by ovarectomy and immobilization,
respectively (Yoshida et al., 2002). The protective effect of EP4 re-
ceptor stimulation against immobilization-induced bone loss is in
line with the observation that mechanical strain applied to human
osteoblasts down-regulates sclerostin, a potent inhibitor of bone for-
mation, via COX-2 induction and EP4 receptor/ERK signaling (Galea
et al., 2011).
Very recently, novel dual-action bone-targeting drug conjugates,
consisting of EP4 receptor agonists and a bisphosphonate, alendronic
acid, were reported (Arns et al., 2012). Radiolabeled conjugates of
these drugs were administered to rats and were found to be taken up
into the bone and released subsequently in a sustained manner,
suggesting an attractive novel approach tomodulating bonemetabolism.
PGE2 and EP4 receptors may play a similar, dual role in cartilage
homeostasis and arthritis. In cartilage of osteoarthritis patients PGE2
acting via EP4 receptors attenuated chondrocyte expression of connec-
tive tissue growth factor (Masuko et al., 2010), inhibited proteoglycan
synthesis and promoted matrix degradation (Attur et al., 2008), while
it also stimulated the release of osteoclast-activating factor RANKL
(Moreno-Rubio et al., 2010).
Moreover, the EP4 receptor seems to be involved in inﬂammatory
pain in experimental arthritis models and to promote Th1 differentia-
tion, Th17 cell expansion, and IL-23 secretion by activated dendritic
cells (Yao et al., 2009; Chen et al., 2010). Consequently, EP4 antagonists
might have analgesic and anti-inﬂammatory effects in arthritis (Omote
et al., 2002; Okumura et al., 2008; Colucci et al., 2010). Ultimately,
EP4 knock-out mice were found to be resistant to type-II collagen
antibody-induced arthritis (McCoy et al., 2002). In a positive feed-
back loop, EP4 receptors are upregulated in arthritic tissue (Kurihara
et al., 2001).
On the other hand, EP4 receptor activation in chondrocytes
has been linked to PGE2-induced inhibition of matrix metalloprotease
expression (Fushimi et al., 2007; Nishitani et al., 2010). In an ex vivo
model of human pannus formation, i.e. aberrant proliferation of syno-
vial tissue leading to joint destruction, endogenous PGE2 via activating
its EP4 receptor, inhibited pannus growth and osteoclast activity
(Shibata-Nozaki et al., 2011). These ﬁndings might be consistent with
a crucial role of EP4 receptors in promoting acute inﬂammatory
responses and pain in arthritis, but also with limiting cartilage and
bone destruction in the chronic phase.
10. Cancer
The role of prostaglandins has extensively been studied in cancer,
and COX-2 has emerged as a potential therapeutic target in some
tumors. COX-2 expression has been found to correlate with cancer
progression in experimental models and in many types of cancers,
and pharmacological inhibition or genetic ablation of COX-2 reduces
tumor cell proliferation and metastasis (Cebola & Peinado, 2012).
Moreover, long-term administration of COX inhibitors such as
acetylsalicylic acid can exert signiﬁcant prophylactic effects against
certain cancers (Harris, 2009). The signiﬁcant adverse effects of COX
inhibitors need to be considered, though, and might be avoided by
selectively addressing the respective receptors for prostaglandins
instead of non-selectively inhibiting prostaglandin production.
Revisiting the roles of different EP receptors in cancer development,
a large body of evidence supports EP4 receptors to predominantly
mediate the overall pro-tumorigenic action of PGE2. The potential
involvement of EP4 receptors has been described in many different
types of cancer. Activation of EP4may confer diverse cellular responses,
such as promoting angiogenesis, proliferation, motility and metastasis,
or delaying apoptosis, of tumor cells. These notions are based on studies
using selective EP4 antagonists and agonists as well as mice that havebeenmade deﬁcient in EP4 receptors. In agreementwith these ﬁndings,
EP4 receptors are expressed on sprouting angiogenic cells, immune
cells and the tumor cells itself, which are activated by PGE2 in an
autocrine or paracrine manner.
For instance, EP4 receptor expression was observed to increase
during transition of colorectal adenoma to carcinoma (Chell et al.,
2006) and EP4 receptor over-expression favored an anchorage-
independent phenotype in otherwise anchorage-dependent human
colorectal adenoma cells (Chell et al., 2006; Hawcroft et al., 2007).
Consistently, the EP4 antagonist ONO AE3-208 attenuated colony
forming capacity. PGE2 stimulates migration of colon cancer cells via
EP4/β-arrestin 1/c-Src signaling that transactivates and phosphorylates
the epidermal growth factor receptor (Buchanan et al., 2006).
EP4 receptor over-expression resulted in the suppression of apoptosis
in a cAMP/CREB-dependent manner, and enhanced anchorage-
independent growth, of a human colon cancer cell line (Hawcroft
et al., 2007). In a different colon carcinoma cell line EP4 receptor was
found to drive in vivo growth by augmenting tumor vascularization,
and delaying apoptosis (Pozzi et al., 2004), while colon carcinogenesis
was inhibited in mice lacking EP4 but not EP2 receptors, and by the
EP4 antagonist ONO AE2-227 (Mutoh et al., 2002). Interestingly, over-
expression of k-Ras, an oncogene involved in malignant transformation
of many tumors, facilitated COX-2 and EP4 receptor expression in colon
carcinoma cells (Wu et al., 2010).
EP4 mRNA levels were also found elevated in cervical carcinoma
compared with normal cervix (Sales et al., 2001), and expression of
COX-2 and EP4 receptors in transitional cell carcinoma of the upper
urinary tract was associated with metastasis and shorter survival of
patients (Miyata et al., 2005). COX-2 derived PGE2 stimulated the
migration and CCR7 expression of breast cancer cells via EP4 receptors
linked to PKA and Akt signaling (Timoshenko et al., 2003; Pan et al.,
2008). In a murine breast cancer model, EP4 receptors promoted
lymphangiogenesis and ensuing metastasis (Xin et al., 2012). In breast
cancer patients, expression of the EP4 receptor correlated with en-
hanced lymphatic invasion (Pan et al., 2008), and the EP4 antagonists,
AH23848 and ONO AE3-208, attenuated lung metastasis of these
tumor cells in mice, while ONO-AE2-227 prevented their osteolytic
activity in vitro (Ohshiba et al., 2003; Ma et al., 2006). Similarly, EP4
receptor stimulation resulted in cAMP/EPAC-mediated activation of
RAP small GTPase and augmented migration of renal carcinoma cells
(Wu et al., 2011). Ovarian cancer cells responded to activation of
PGE2/EP4 receptor signaling with VEGF expression and tumor cell
invasion, by activating tumor-associated matrix metalloproteinases
(Spinella et al., 2004). EP4 receptors facilitated pulmonary metastasis
of lung carcinoma cells injected intravenously in mice and liver metas-
tasis after intrasplenic injection of colon cancer cells (Yang et al., 2006).
Treatment of mice with ONO AE3-208 or siRNA knock-down of EP4
receptor in the tumor cells ameliorated tumor growth and metastasis.
In mouse skin, overexpression of EP4 receptors enhanced non-
melanoma skin tumorigenesis (Rundhaug et al., 2011), and PGE2 act-
ing via EP4 receptors stimulated the migration of human melanoma
cells (Singh et al., 2011). Consistently, the EP4 antagonist ONO AE3-
208 prevented melanoma-induced bone metastasis and osteolysis in
mice (Takita et al., 2007). Other types of cancer that might be sen-
sitive to EP4 receptor stimulation include mycosis fungoides (Kopp
et al., 2010), pancreatic adenocarcinoma (Funahashi et al., 2008),
esophageal adenocarcinoma (Ogunwobi et al., 2006; Jimenez et al.,
2010), endometrium cancer (Catalano et al., 2011), prostate cancer
(Terada et al., 2010; Miao et al., 2012), neuroblastoma (Rasmuson
et al., 2012), and glioblastoma (Kambe et al., 2009).
In addition to directly stimulating tumor cell proliferation and
motility, EP4 receptor-mediated PGE2 signals can down-regulate
immune responses, thereby hampering tumor-limiting mechanisms.
In detail, tumor-derived PGE2 stimulating EP4 receptors curb natural
killer cell and γδ T cell activity (Kundu et al., 2009; Martinet et al.,
2010; Holt et al., 2011), and cytokine secretion from macrophages
Fig. 4. The effect of EP4 receptor activation in different diseases and cellular processes.
Promotion of a respective response is shown by while indicates inhibi-
tory modulation.
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maturation is blocked and their differentiation is diverted towards a phe-
notype referred to asmyeloid-derived suppressor cells (Obermajer et al.,
2011a, 2011b). Importantly, in a positive feedback loop PGE2 induced
further COX-2 leading to exaggerated PGE2 biosynthesis in immature
myeloid cells (Ogunwobi et al., 2006; Obermajer et al., 2011a). Similarly,
PGE2/EP4 receptor-mediated induction of Foxp3/CD4/CD25+ T regulato-
ry cells was shown to result in enhanced tumor burden in mice injected
with lung cancer cells (Sharma et al., 2005). Conversely, PGE2 supported
the recruitment of tumor-promoting macrophages to mouse gastric
tumors thereby enhancing tumor growth (Oshima et al., 2011).
Taken together, several studies have demonstrated that EP4
antagonists might have beneﬁcial effects on carcinogenesis and tumor
progression. Recent studies, however, suggest that the EP4 receptor
might also act as tumor suppressor, for instance in human B cells
(Murn et al., 2008). The EP4 receptor provides a negative feedback
signal to proliferation in response to B cell receptor activation,
suppressing growth in a PGE2-dependent manner. B cell receptor
activation upregulates EP4 receptors on immature B cells and pro-
motes their apoptosis (Prijatelj et al., 2011). In B cell lymphomas,
EP4 receptors are down-regulated and growth suppression is
diminished (Murn et al., 2008). In another study, activation of EP4
receptors inhibited the growth of four different human gastric
carcinoma cell lines (Okuyama et al., 2002).
11. Miscellaneous
In addition to what is described above, EP4 receptors may be
useful therapeutic targets in various other organs, including eye, inner
ear, brain or female reproductive tract. Topical application of the EP4 ag-
onist prodrug PF-04475270 lowered ocular pressure through its active
metabolite CP-734432 in normotensive dogs (Prasanna et al., 2009).
However, conjunctival hyperemia and corneal neovascularization
were also observed (Aguirre et al., 2009). EP4 knock-out mice exhibit
a slight hearing deﬁcit at baseline and are more susceptible to acoustic
trauma as reﬂected by increased loss of outer hair cells. An EP4 antago-
nist recapitulated these effects while an EP4 agonist prevented hearing
loss in wild-type mice (Hamaguchi et al., 2012). EP2 and EP4 agonists
stimulated the production of VEGF in the spiral ganglion suggesting
a beneﬁcial effect in diseases like acute sensorineural hearing loss
(Hori et al., 2010).
EP4 receptors are also involved in mediating various effects
exerted by PGE2 in female sexual organs. Blockade of EP4 receptors
inhibited the proliferation and invasion of human endometriotic
cells, and induces their apoptosis (Banu et al., 2009; Lee et al.,
2011). PGE2 stimulated follicle maturation in immature rat ovaries
through upregulation of IL-8 and this was mimicked by an EP4
agonist (El-Neﬁawy et al., 2005). An EP4 agonist also stimulated
ovulation in mice (Xiao et al., 2008). In contrast, PGE2 delayed nuclear
maturation and fertilization of mouse and monkey oocytes, probably
through EP2 and/or EP4 receptors (Duffy et al., 2010). Endogenous
PGE2 mediated LPS-induced cervical ripening in rabbits, which
was reversed by an EP4 antagonist (Fukuda et al., 2007). An EP4
antagonist likewise prevented bladder hyperactivity induced by
cyclophosphamide or PGE2 in rats (Chuang et al., 2012).
Finally, EP4 receptors are capable of modulating central nervous
activity. EP4 receptor activation in a murine model of Alzheimer's
disease, EP4 deﬁciency or the EP4 antagonist ONO-AE3-208 decreased
amyloid-β levels in the brain and improved the behavioral performance
of the animals (Hoshino et al., 2012). By contrast, intracerebroventricular
administration of PGE2 or selective EP1 or EP4 agonists to mice caused
anxiolytic-like effects in the elevated plus-maze and open ﬁeld test,
which was not observed in EP4-deﬁcient animals, but could be reversed
after blockade of serotonin 5-HT1A, dopamine D1 and GABAA receptors
(C. Suzuki et al., 2011). In a similar fashion, intracerebroventricular
administration of PGE2 and the EP4 agonist, ONO-AE1-329, suppressedfood intake in mice, and this effect was prevented by EP4 antagonism.
Accordingly, the EP4 agonist also delayed gastric emptying, but elevated
blood glucose levels (Ohinata et al., 2006). EP4 receptors are expressed in
enteroendocrine cells and stimulate the release of incretins, such as
glucagon-like peptide-1, in vitro and in vivo in mice (Coskun et al.,
2013). A potential role of EP4 receptors in metabolic disease is further
supported by enhanced adipogenesis frommouse embryonic ﬁbroblasts
of EP4-deﬁcient mice and by the inhibitory effect of PGE2 acting via EP4
receptors and peroxisome proliferator-activated receptor-γ (Inazumi
et al., 2011).12. Conclusion
EP4 receptors are the most widely expressed PGE2 receptors in the
body, and research over the past ten years or so has unraveled that
numerous novel, or well-recognized biological effects of PGE2 can
be attributed to EP4 receptor activation (Fig. 4). Among these are
several anti-inﬂammatory roles, modulation of tissue development
and regeneration, and regulation of vascular tone and hemostasis.
In contrast to these EP4 receptor-mediated, assumingly beneﬁcial
actions of PGE2, pathogenic roles of EP4 receptors have been implicated
in cancer growth and metastasis, and in some inﬂammatory diseases.
As such, both EP4 receptor agonists and antagonists might become
useful novel drug classes. Accordingly, the pharmaceutical industry
has launched numerous EP4 drug development programs, and a variety
of EP4 receptor agonists and antagonists have become available for
experimental studies and further clinical development. While systemic
administration of EP4 receptor antagonists might be well tolerated,
agonists are better administered locally, thereby avoiding systemic
side effects. Moreover, in consideration of the sometimes redundant
biological roles of EP2 and EP4 receptors, dual EP2/EP4 antagonists
might be of advantage. Finally, ligand-biased selectivity of EP4 receptor
signaling may exist for Gαs, Gαi and β-arrestin-dependent pathways
and should be taken into consideration when interpreting biological
effects of different EP4 ligands.
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